Pembrolizumab KEYNOTE-001: an adaptive study leading to accelerated approval for two indications and a companion diagnostic

Kang S. P.; Gergich K.; Lubiniecki G. M.; de Alwis D. P.; Chen C.; Tice M. A. B.; Rubin E. H.

首页> 外文期刊>Annals of oncology: official journal of the European Society for Medical Oncology >Pembrolizumab KEYNOTE-001: an adaptive study leading to accelerated approval for two indications and a companion diagnostic

【24h】

Pembrolizumab KEYNOTE-001: an adaptive study leading to accelerated approval for two indications and a companion diagnostic

机译：Pembrolizumab Keynote-001：一种适应性研究，导致加速两个适应症和伴侣诊断的批准

获取原文

获取原文并翻译 | 示例

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

文献代查 >>

页面导航

著录项
相似文献
相关主题

著录项

来源
《Annals of oncology: official journal of the European Society for Medical Oncology》 |2017年第6期|共11页
作者
Kang S. P.; Gergich K.; Lubiniecki G. M.; de Alwis D. P.; Chen C.; Tice M. A. B.; Rubin E. H.;
展开▼
作者单位

Merck &

Co Inc Kenilworth NJ 07033 USA;

Merck &

Co Inc Kenilworth NJ 07033 USA;

Merck &

Co Inc Kenilworth NJ 07033 USA;

Merck &

Co Inc Kenilworth NJ 07033 USA;

Merck &

Co Inc Kenilworth NJ 07033 USA;

Merck &

Co Inc Kenilworth NJ 07033 USA;

Merck &

Co Inc Kenilworth NJ 07033 USA;

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类肿瘤学;
关键词

相似文献

外文文献
中文文献
专利

1. Pembrolizumab KEYNOTE-001: an adaptive study leading to accelerated approval for two indications and a companion diagnostic [J] . Kang S. P., Gergich K., Lubiniecki G. M., Annals of oncology: official journal of the European Society for Medical Oncology . 2017,第6期

机译：Pembrolizumab Keynote-001：一种适应性研究，导致加速两个适应症和伴侣诊断的批准
2. Five-Year Overall Survival for Patients With Advanced Non-Small-Cell Lung Cancer Treated With Pembrolizumab: Results From the Phase I KEYNOTE-001 Study [J] . Garon Edward B., Hellmann Matthew D., Rizvi Naiyer A., Journal of Clinical Oncology . 2019,第28期

机译：用Pembrolizumab处理的晚期非小细胞肺癌患者的五年整体存活：I阶段I次键-001研究的结果
3. Pembrolizumab in patients with advanced non-small-cell lung cancer (KEYNOTE-001): 3-year results from an open-label, phase 1 study [J] . Leigh Natasha B., Hellmann Matthew D., Hui Rina, The lancet. Respiratory medicine. . 2019,第4期

机译：Pembrolizumab患者高级非小细胞肺癌（Keynote-001）：开放标签的3年结果，第1阶段研究
4. Adaptive Companion-Mediated Behavior Changes on Arithmatopia Games User: Case Study of NPC Design [C] . Alfika Nursyahrinanto Muis, Ary Setijadi Prihatmanto, Gilang Ridzwanda Esthian Gitarana, International Conference on Interactive Digital Media . 2020

机译：Activeive Companion介导的行为发生在arithmatopia游戏用户的变化：NPC设计的案例研究
5. A Case Study of Next-Generation Sequencing Operationalization in an Oncology Companion Diagnostic Environment [D] . ?Patriquin, Caitlin McMahon 2020

机译：新一代测序可操作性，在肿瘤学协同诊断环境为例
6. Pembrolizumab KEYNOTE-001: an adaptive study leading to accelerated approval for two indications and a companion diagnostic [O] . S. P. Kang, K. Gergich, G. M. Lubiniecki, -1

机译：Pembrolizumab KEYNOTE-001：一项适应性研究导致两个适应症和一个伴随诊断的加速批准
7. Keynote-158 study, FDA granted accelerated approval of pembrolizumab for the treatment of patients with advanced PD-L1-positive cervical cancer [O] . Edith Borcoman, Christophe Le Tourneau 2020

机译：keynote-158研究，FDA授予Pembrolizumab的加速批准用于治疗晚期PD-L1阳性宫颈癌患者

Pembrolizumab KEYNOTE-001: an adaptive study leading to accelerated approval for two indications and a companion diagnostic

著录项

相似文献

相关主题

期刊订阅